UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/600/0.1/18.12.24 | Market Closed - BOERSE MUENCHEN 20:41:29 14/06/2024 BST | ||
| 0.77 EUR | +2.67% |
|
| Current month | +50.98% | ||
| 1 month | +175.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 0.77 | +2.67% |
| 13/06/24 | 0.75 | +5.63% |
| 12/06/24 | 0.71 | -17.44% |
| 11/06/24 | 0.86 | -4.44% |
| 10/06/24 | 0.9 | -6.25% |
Real-time BOERSE MUENCHEN
Last update June 14, 2024 at 08:41 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD1KPG |
| ISIN | DE000HD1KPG9 |
| Date issued | 02/01/2024 |
| Strike | 600 $ |
| Maturity | 18/12/2024 (186 Days) |
| Parity | 10 : 1 |
| Emission price | 0.88 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.57 € |
|---|---|
| Lowest since issue | 0.051 € |
| Spread | 0.04 € |
| Spread % | 5.13% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Warrants
- Warrant
